Store
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029
Publication Date: March 4, 2025
Tags: COVID-19, Diagnostic Instruments, Molecular Diagnostics, Point-of-Care (POC) Testing
Pages: 140
SKU: 25-018KA
Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information’s latest report, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.
Market Drivers & Opportunities:
mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.
With leading companies such as Abbott, Cepheid, bioMérieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:
- What is the size and projected growth of the mPOC market?
- Which companies are leading the market, and how are they positioned?
- How is mPOC impacting traditional laboratory-based molecular testing?
- What regions and disease segments present the greatest opportunities?
Comprehensive Market Insights:
This report offers detailed segmentation of the mPOC market, including:
- Market Sizing & Forecasts (2024-2029) – Revenue projections by technology, region, and disease area.
- Competitive Analysis – Market share breakdowns and insights into leading companies.
- Geographic Trends – Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
- Technology & Regulatory Landscape – Overview of CLIA-waived and moderate-complexity molecular platforms.
Scope:
Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029 provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.
This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between “true” molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market’s growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.
A Decade of mPOC Research Expertise:
Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029, offers critical insights to help you navigate and capitalize on this fast-growing segment.
Table: mPOC and Near-Patient Market, 2024-2029 ($ million)
| Year | mPOC | Near Patient |
| 2024 | $XX Million | $XX Million |
| 2025 | $XX Million | $XX Million |
| 2026 | $XX Million | $XX Million |
| 2027 | $XX Million | $XX Million |
| 2028 | $XX Million | $XX Million |
| 2029 | $XX Million | $XX Million |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
- Figure 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
- Figure 1-2: Near Patient Molecular Systems Market, 2024-2029 ($ million)
Where is Molecular Point-of-Care in 2025?
- Table 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
Molecular Point-of-Care Market Analysis
- Table 1-2: Molecular Point-of-Care Market Growth, 2024-2029 (%)
- Figure 1-3: Molecular Point-of-Care Market, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
Market Observations
“Near-Patient” Molecular Systems Market
- Table 1-3: Near Patient Molecular Systems Market, 2024-2029 ($ million)
- Table 1-4: Near Patient Molecular Systems Market Growth, 2024-2029 (%)
- Table 1-5: mPOC and Near-Patient Market, 2024-2029 ($ million)
- Figure 1-4: mPOC and Near-Patient Market, 2024-2029 ($ million)
Current Trends
Molecular Point-of-Care Diagnostics Defined
Usage of Molecular Point-of-Care
Leading mPOC Platforms
- Table 1-6: Molecular POC Diagnostic Platforms and Technologies
Trends
Scope and Methodology
Chapter 2: Molecular Point-of-Care Market Development and Trends
COVID-19 and Molecular POC
- Table 2-1: Molecular POC COVID-19 Emergency Authorizations
CDC Initial Response, Long Term Situation
COVID-19’s Unique Challenge
BARDA Directs Funding to mPOC
Regulatory Developments
Consortia, Funding, Prizes
Deals
- Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
Advantages and Disadvantages of Molecular Point-of-Care
- Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
Justification: The Sensitivity/Specificity Argument
New Systems and Menu Expansion
New Systems Introduced in Development
Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
STI Continues to Be a Growth Area
Deals, Investment in mPOC Systems
Roche Acquires LumiraDx for up to $350 Million
Thermo Acquires Mesa Biotech
China as a POC Market
Common Tests and Analytes in POC Diagnostics
Component Technologies of Molecular Point-of-Care Diagnostics
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
Molecular Diagnostics
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Loop-Mediated Isothermal Amplification (LAMP)
Nicking Enzyme Amplification Reaction (NEAR)
Strand Displacement Amplification (SDA)
Helicase Dependent Amplification (HDA)
Nucleic Acid Sequence-Based Amplification (NASBA)
Transcription-Mediated Amplification (TMA)
Cross Priming Amplification (CPA)
Line Probe Assays
Applications and Potential Applications for Molecular Point-of-Care
Major Testing Applications for Molecular POC Diagnostics
Influenza
Reclassification of RIDTs
Hospital-Acquired Infections (HAIs)
Strep A
Respiratory Syncytial Virus (RSV)
Emerging Applications
Zika
Other Respiratory Infections
Group B Streptococcus
Human Papillomavirus
Herpes Simplex Virus
Vaginitis
Tuberculosis
Malaria
Other Tropical and Neglected Diseases
Cancer
European Device Regulations
Chapter 3: Market Analysis
Molecular Point-of-Care Market Analysis
- Table 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
- Figure 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
Regional Shares
- Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Figure 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
- Figure 3-3: Global Molecular Point-of-Care Market Share, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
Breakout by Disease Area
- Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
- Figure 3-4: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
- Figure 3-5: Breakout of Molecular Point-of-Care Market Share, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
“Near Patient Molecular” Market
- Table 3-4: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
- Figure 3-6: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million)
Vendor Market Share for Near Patient Molecular Testing
- Table 3-5: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMérieux, Cepheid, Roche, Other]
- Figure 3-7: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMérieux, Cepheid, Roche, Other]
Chapter 4: Company Profiles
Abbott Laboratories
Aidian Oy
Akonni Biosystems
binx health, inc.
Biocartis NV
bioMérieux SA
- Table 4-1: bioMérieux FilmArray Est. Systems per Quarter, Q4 ’18-Q4 ’24
- Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q4 2024
Cepheid (Danaher)
Molecular Healthcare-Acquired Infection (HAI) Testing
Molecular Sexual Health and Women’s Health Testing
Molecular Critical Infectious Disease Testing
Molecular Oncology/Genetics Testing
Credo Diagnostics Biomedical Pte. Ltd.
Curetis NV (OpGen)
DiaSorin S.p.A
GenMark Diagnostics (Roche)
Greiner Bio-One GmbH
Lucira Health (Pfizer)
Meridian Bioscience, Inc. (SD Biosensor)
Mesa Biotech, Inc. (Thermo)
QIAGEN NV
QuantuMDx Group
QuidelOrtho Corporation
Roche
Sekisui Diagnostics LLC
T2 Biosystems
Related products
Hematology and Coagulation Markets, 2023
April 5, 2023
Discover the lucrative $10 billion-dollar market for hematology and coagulation in vitro diagnostic (IVD) testing with Kalorama’s comprehensive report, Hematology and Coagulation Markets, 2023. This analysis delves into the dynamic growth factors driving this market, including new technologies, the aging population, and the increasing demand for decentralized testing.
Key Insights Provided:
- Market sizing…
Price range: $3,000.00 through $4,500.00
The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition
March 7, 2024
Explore the cutting-edge world of molecular point-of-care (mPOC) diagnostic solutions with our latest report, offering a detailed analysis of the market and future growth potential from 2023-2028. mPOC technology revolutionizes diagnostic capabilities, providing enhanced sensitivity and specificity compared to traditional near-patient tests. These solutions are instrumental in critical care units, physician offices, outpatient clinics,…
Price range: $5,000.00 through $7,875.00
The World Market for Vaccines, 2024
February 22, 2024
Vaccines are a cornerstone of preventive medicine, offering long-term or permanent immunity against diseases. They have been instrumental in near-eliminating many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century. Kalorama Information’s latest report, The World Market for Vaccines, 2024, provides a comprehensive analysis of adult…
Price range: $5,000.00 through $7,875.00
